MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 200283 | Name: Tivantinib
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-Met protein and disrupts c-Met signal transduction pathways, which may induce cell death in tumor cells overexpressing c-Met protein or expressing consitutively activated c-Met protein. c-Met protein, the product of the proto-oncogene c-Met, is a receptor tyrosine kinase also known as hepatocyte growth factor receptor (HGFR); this protein is overexpressed or mutated in many tumor cell types and plays key roles in tumor cell proliferation, survival, invasion, and metastasis, and tumor angiogenesis.

Chemical Structure

Tivantinib
Tivantinib
CAS#905854-02-6

Theoretical Analysis

MedKoo Cat#: 200283

Name: Tivantinib

CAS#: 905854-02-6

Chemical Formula: C23H19N3O2

Exact Mass: 369.1477

Molecular Weight: 369.41

Elemental Analysis: C, 74.78; H, 5.18; N, 11.37; O, 8.66

Price and Availability

Size Price Availability Quantity
5mg USD 250.00 2 Weeks
10mg USD 350.00 2 Weeks
50mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ARQ197; ARQ 197; ARQ-197; Tivantinib
IUPAC/Chemical Name
(3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione
InChi Key
UCEQXRCJXIVODC-PMACEKPBSA-N
InChi Code
InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1
SMILES Code
O=C([C@@H](C1=CN2CCCC3=C2C1=CC=C3)[C@@H]4C5=CNC6=C5C=CC=C6)NC4=O
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 369.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chilamakuri R, Agarwal S. Repurposing of c-MET Inhibitor Tivantinib Inhibits Pediatric Neuroblastoma Cellular Growth. Pharmaceuticals (Basel). 2024 Oct 9;17(10):1350. doi: 10.3390/ph17101350. PMID: 39458991; PMCID: PMC11510580. 2: Lu F, Zhao K, Ye M, Xing G, Liu B, Li X, Ran Y, Wu F, Chen W, Hu S. Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. BMC Cancer. 2024 Aug 19;24(1):1023. doi: 10.1186/s12885-024-12780-y. PMID: 39160484; PMCID: PMC11331808. 3: Oraiopoulou ME, Couturier DL, Bunce EV, Cannell IG, Sweeney PW, Naylor H, Golinska M, Hannon GJ, Sakkalis V, Bohndiek SE. The in vitro dynamics of pseudo- vascular network formation. Br J Cancer. 2024 Aug;131(3):457-467. doi: 10.1038/s41416-024-02722-7. Epub 2024 Jun 20. PMID: 38902534; PMCID: PMC11300916. 4: Abduljalil JM, Elfiky AA, AlKhazindar MM. Tepotinib and tivantinib as potential inhibitors for the serine/threonine kinase of the mpox virus: insights from structural bioinformatics analysis. J Biomol Struct Dyn. 2024 Mar 26:1-11. doi: 10.1080/07391102.2024.2323699. Epub ahead of print. PMID: 38529847. 5: Vahabi M, Xu G, Avan A, Peters GJ, Giovannetti E. Pharmacological mechanisms underlying the interaction of the nucleoside analogue gemcitabine with the c-MET inhibitor tivantinib in pancreatic cancer. Nucleosides Nucleotides Nucleic Acids. 2024;43(8):837-850. doi: 10.1080/15257770.2024.2319215. Epub 2024 Feb 29. PMID: 38420938. 6: Redmer T, Schumann E, Peters K, Weidemeier ME, Nowak S, Schroeder HWS, Vidal A, Radbruch H, Lehmann A, Kreuzer-Redmer S, Jürchott K, Radke J. MET receptor serves as a promising target in melanoma brain metastases. Acta Neuropathol. 2024 Feb 22;147(1):44. doi: 10.1007/s00401-024-02694-1. Erratum in: Acta Neuropathol. 2024 Mar 27;147(1):63. doi: 10.1007/s00401-024-02719-9. PMID: 38386085; PMCID: PMC10884227. 7: Mohamady S, Khalil AF, Naguib BH, Nafie MS, Tawfik HO, Shaldam MA. Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study. Bioorg Chem. 2024 Feb;143:106988. doi: 10.1016/j.bioorg.2023.106988. Epub 2023 Nov 20. PMID: 37995644. 8: Wang Y, Xu H, Yang J, Zhang J. The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis. Medicine (Baltimore). 2023 Apr 21;102(16):e32591. doi: 10.1097/MD.0000000000032591. PMID: 37083791; PMCID: PMC10118349. 9: Huang Y, Guo Y, Zhou Y, Huang Q, Ru Y, Luo Y, Xu W. Tivantinib alleviates inflammatory diseases by directly targeting NLRP3. iScience. 2023 Feb 1;26(3):106062. doi: 10.1016/j.isci.2023.106062. PMID: 36843841; PMCID: PMC9950949. 10: Kang J, Deng QM, Feng W, Chen ZH, Su JW, Chen HJ, Wang WX, Zhang S, Wang Q, Chen Z, Zhong WZ, Xu CW, Yang JJ. Response and acquired resistance to MET inhibitors in de novo MET fusion-positive advanced non-small cell lung cancer. Lung Cancer. 2023 Apr;178:66-74. doi: 10.1016/j.lungcan.2023.01.017. Epub 2023 Feb 1. PMID: 36806896. 11: Wang S, Bai J, Wang K, Guo Y. Carbon fiber paper spray ionization mass spectrometry. Anal Chim Acta. 2022 Nov 1;1232:340477. doi: 10.1016/j.aca.2022.340477. Epub 2022 Oct 3. PMID: 36257747. 12: Zhao J, Birjandi AA, Ahmed M, Redhead Y, Olea JV, Sharpe P. Telocytes regulate macrophages in periodontal disease. Elife. 2022 Oct 4;11:e72128. doi: 10.7554/eLife.72128. PMID: 36193890; PMCID: PMC9576272. 13: Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y. Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now? Biomedicines. 2022 Aug 29;10(9):2113. doi: 10.3390/biomedicines10092113. PMID: 36140214; PMCID: PMC9495728. 14: He Y, Zeng J, Wei Z, Huang Y, Yang L, Hu X, Su Y, Peng X. Comparison of Second-Line Treatments for Patients with Platinum-Resistant Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Systematic Review and Bayesian Network Meta-Analysis. Cancers (Basel). 2022 Sep 15;14(18):4472. doi: 10.3390/cancers14184472. PMID: 36139631; PMCID: PMC9497217. 15: Chen Q, Du X. FGF/FGFR-related lncRNAs based classification predicts prognosis and guides therapy in gastric cancer. Front Genet. 2022 Aug 29;13:948102. doi: 10.3389/fgene.2022.948102. PMID: 36105076; PMCID: PMC9465033. 16: Xiao Y, Zhang B, Cloyd JM, Alaimo L, Xu G, Du S, Mao Y, Pawlik TM. Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. Cancers (Basel). 2022 Jul 5;14(13):3284. doi: 10.3390/cancers14133284. PMID: 35805055; PMCID: PMC9265136. 17: Jiang W, Zhao T, Zhen X, Jin C, Li H, Ha J. Rapid Determination of 9 Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma in Human Plasma by QuEChERS-UPLC-MS/MS. Front Pharmacol. 2022 Jun 21;13:920436. doi: 10.3389/fphar.2022.920436. PMID: 35800447; PMCID: PMC9253689. 18: Lian T, Zhang X. The Role of Tyrosine Kinase Inhibitors in Reduction of Mortality from Non-small Cell Lung Cancer: A Meta-analysis. Comb Chem High Throughput Screen. 2023;26(5):928-937. doi: 10.2174/1386207325666220701122755. PMID: 35786333. 19: Luo GL, Guo BQ, Wu LX, Shen YX, Xie T. Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study. Evid Based Complement Alternat Med. 2022 Jun 7;2022:1976788. doi: 10.1155/2022/1976788. PMID: 35711496; PMCID: PMC9197645. 20: Thomas A, Slade KS, Blaheta RA, Markowitsch SD, Stenzel P, Tagscherer KE, Roth W, Schindeldecker M, Michaelis M, Rothweiler F, Cinatl J, Dotzauer R, Vakhrusheva O, Albersen M, Haferkamp A, Juengel E, Cinatl J Jr, Tsaur I. Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer. Cancers (Basel). 2022 Mar 25;14(7):1683. doi: 10.3390/cancers14071683. PMID: 35406455; PMCID: PMC8997038.